← All trials
NCT04361942
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Dec 31, 2020
- First posted
- Apr 24, 2020
- Last posted
- Apr 29, 2020
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Red de Terapia CelularLead sponsor
- Universidad Carlos III MadridCollaborator
- University of ValladolidOverall official - principal investigator
- University of ValladolidCollaborator
- Hospital Rio HortegaCollaborator
- Castilla-Leon Health ServiceCollaborator
- CitospinCollaborator
- Hospital Rio HortegaStudy chair
- Hospital Rio HortegaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.